Trinity Biotech

Trinity Biotech Financial Debt Ratio

The Financial Debt Ratio of Trinity Biotech (TRIB) as of Nov 10, 2026 is 131.21 %. In the previous year, Financial Debt Ratio was 97.55 % — a change of 34.50% (higher).

Financial Debt Ratio

131.21 %

YoY

34.50%

Last updated:

Financial Debt Ratio of Trinity Biotech is 2025 131.21 % . Financial Debt Ratio of Trinity Biotech was 2024 97.55 % . It decreases by 34.50% higher compared to the previous year.

The Trinity Biotech Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2018
54.26 USD
Jan 1, 2019
77.95 USD
Jan 1, 2020
80.02 USD
Jan 1, 2021
83.40 USD
Jan 1, 2022
78.39 USD
Jan 1, 2023
113.45 USD
Jan 1, 2024
97.55 USD
Jan 1, 2025
131.21 USD
The Trinity Biotech Financial Debt Ratio history
YEARFinancial Debt RatioYoY
131.21 %+34.50%
97.55 %-14.01%
113.45 %+44.72%
78.39 %-6.01%
83.40 %+4.23%
80.02 %+2.65%
77.95 %+43.67%
54.26 %+9.80%
49.41 %+27.46%
38.77 %+41.94%
27.31 %+370.51%
5.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Financial Debt Ratio of Trinity Biotech is 131.21 % in 2025.

Financial Debt Ratio of Trinity Biotech changed from 97.55 % to 131.21 %, representing a 34.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's Trinity Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Trinity Biotech

All Key Metrics — Trinity Biotech